Sign in Subscribe
Class action lawsuits

Novo Nordisk A/S Faces Class Action Lawsuit from National Plaintiffs' Law Firm

Strategic Insights

— 1 min read

A national plaintiffs' law firm has filed a class action lawsuit against Novo Nordisk A/S, alleging that the pharmaceutical company understated the impact of the personalization exception to the compounded GLP-1 exclusion, thereby overstating its ability to sustain long-term growth. The lawsuit claims that Novo Nordisk overstated the likelihood that patients using compounded alternatives would switch to its branded products. On July 29, 2025, Novo Nordisk announced a sales and profit outlook revision, citing slower-than-expected growth for its products Wegovy and Ozempic. Following the announcement, the company's stock price plummeted, dropping by approximately 21.83% in a single day.

Key Takeaways:

  • The lawsuit alleges that Novo Nordisk understated the impact of the personalization exception to the compounded GLP-1 exclusion, resulting in overstatement of its ability to sustain long-term growth.
  • The company is accused of overstating the likelihood that patients using compounded alternatives would switch to its branded products.
  • Novo Nordisk announced a sales and profit outlook revision on July 29, 2025, citing slower-than-expected growth for Wegovy and Ozempic.
  • The company's stock price dropped by 21.83% in a single day following the announcement.
  • The lawsuit aims to recover damages for investors who purchased Novo Nordisk securities from May 7, 2025 through July 28, 2025.
  • Berger Montague, the national plaintiffs' law firm, is representing the investors in the class action lawsuit.
  • Andrew Abramowitz and Caitlin Adorni are the attorneys representing the plaintiffs.

Statistics:

  • The lawsuit covers a period from May 7, 2025 to July 28, 2025, during which time investors allegedly purchased or otherwise acquired publicly traded securities of Novo Nordisk A/S.
  • On July 29, 2025, Novo Nordisk's stock price dropped from $69.00 per share to $53.94 per share, a decline of approximately 21.83%.
  • The Company cited slower-than-expected growth for Wegovy and Ozempic as the reason for the guidance revision.
  • The investor deadline to seek appointment as a lead plaintiff representative of the class is September 30, 2025.

Sources:

  • Globe Newswire - Aug. 04, 2025, "National Plaintiffs' Law Firm Announces Class Action Lawsuit Against Novo Nordisk A/S (NYSE: NVO)".
  • Berger Montague's website - "Class Action Lawsuit Filed on Behalf of Novo Nordisk A/S (NYSE: NVO) Investors".
  • Globe Newswire - July 29, 2025, "Novo Nordisk A/S (NYSE: NVO) announces revised sales and profit outlook for fiscal 2025".

Read more